Efficacy and safety of triple or dual therapies for metastatic hormone-sensitive prostate cancer: a systematic review and Bayesian network meta-analysis

References

• Sung H, Ferlay J, Siegel RL et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
   PubMed Web of Science ®Google Scholar
• Kelly SP, Anderson WF, Rosenberg PS et al. Past, current, and future incidence rates and burden of metastatic prostate cancer in the United States. Eur. Urol. Focus 4(1), 121–127 (2018).
   PubMedGoogle Scholar
• Lowrance WT, Murad MH, Oh WK et al. Castration-resistant prostate cancer: AUA Guideline Amendment 2018. J. Urol. 200(6), 1264–1272 (2018).
   PubMed Web of Science ®Google Scholar
• Fizazi K, Tran N, Fein L et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 20(5), 686–700 (2019).
   PubMed Web of Science ®Google Scholar
• Hoyle AP, Ali A, James ND et al. Abiraterone in “high-” and “low-risk” metastatic hormone-sensitive prostate cancer. Eur. Urol. 76, 719–728 (2019).
   PubMed Web of Science ®Google Scholar
• Davis ID, Martin AJ, Stockler MR et al. ENZAMET trial investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381(2), 121–131 (2019).
   PubMed Web of Science ®Google Scholar
• Chi KN, Chowdhury S, Bjartell A et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J. Clin. Oncol. 39(20), 2294–2303 (2021).
   PubMed Web of Science ®Google Scholar
• Armstrong AJ, Szmulewitz RZ, Petrylak DP et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 37(32), 2974–2986 (2019).
   PubMed Web of Science ®Google Scholar
• Sydes MR, Spears MR, Mason MD et al. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann. Oncol. 29, 1235–1248 (2018).
   PubMed Web of Science ®Google Scholar
• Clarke NW, Ali A, Ingleby FC et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann. Oncol. 30(12), 1992–2003 (2019).
   PubMed Web of Science ®Google Scholar
• Gravis G, Boher JM, Joly F et al. Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 Trial. Eur. Urol. 70(2), 256–262 (2016).
   PubMed Web of Science ®Google Scholar
• Kyriakopoulos CE, Chen YH, Carducci MA et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J. Clin. Oncol. 36(11), 1080–1087 (2018).
   PubMed Web of Science ®Google Scholar
• Gu W, Han W, Luo H et al. Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial. Lancet Oncol. 23(10), 1249–1260 (2022).
   Web of Science ®Google Scholar
• Fizazi K, Foulon S, Carles J et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet 399(10336), 1695–1707 (2022).
   PubMed Web of Science ®Google Scholar
• Smith MR, Hussain M, Saad F et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS study. Future Oncol. 18(21), 2585–2597 (2022).
   PubMed Web of Science ®Google Scholar
• Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J. Clin. Oncol. 26(7), 1148–1159 (2008).
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45(2), 228–247 (2009).
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343, d5928 (2011).
   PubMed Web of Science ®Google Scholar
• van Valkenhoef G, Lu G, de Brock B et al. Automating network meta-analysis. Res. Synth. Methods 3(4), 285–299 (2012).
   PubMed Web of Science ®Google Scholar
• van Valkenhoef G, Dias S, Ades AE et al. Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis. Res. Synth. Methods 7(1), 80–93 (2016).
   PubMed Web of Science ®Google Scholar
• Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial. J. Clin. Epidemiol. 64(2), 163–171 (2011).
   PubMed Web of Science ®Google Scholar
• Roy S, Sayyid R, Saad F et al. Addition of docetaxel to androgen receptor axis-targeted therapy and androgen deprivation therapy in metastatic hormone-sensitive prostate cancer: a network meta-analysis. Eur. Urol. Oncol. 5(5), 494–502 (2022).
   Web of Science ®Google Scholar
• Feyerabend S, Saad F, Li T et al. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: a network meta-analysis. Eur. J. Cancer 103, 78–87 (2018).
   PubMed Web of Science ®Google Scholar
• Mori K, Mostafaei H, Sari Motlagh R et al. Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. BJU Int. 129(4), 423–433 (2022).
   Web of Science ®Google Scholar
• Rush HL, Murphy L, Morgans AK et al. Quality of life in men with prostate cancer randomly allocated to receive docetaxel or abiraterone in the STAMPEDE trial. J. Clin. Oncol. 40(8), 825–836 (2022).
   Web of Science ®Google Scholar
• Thomas C, Baunacke M, Erb HHH et al. Systemic triple therapy in metastatic hormone-sensitive prostate cancer (mHSPC): ready for prime time or still to be explored?. Cancers (Basel) 14(1), 8 (2021).
   Web of Science ®Google Scholar
• Han H, Lee HH, Choi K et al. Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype. Prostate Cancer Prostatic Dis. 24(4), 1080–1092 (2021).
   Web of Science ®Google Scholar
• West J, You L, Zhang J et al. Towards multidrug adaptive therapy. Cancer Res. 80(7), 1578–1589 (2020).
   PubMed Web of Science ®Google Scholar
• Pinto F, Dibitetto F, Ragonese M et al. Mechanisms of resistance to second-generation antiandrogen therapy for prostate cancer: actual knowledge and perspectives. Med. Sci. (Basel) 10(2), 25 (2022).
   Google Scholar
• Yuan F, Hankey W, Wu D et al. Molecular determinants for enzalutamide-induced transcription in prostate cancer. Nucleic Acids Res. 47(19), 10104–10114 (2019).
   Web of Science ®Google Scholar
• Gim HJ, Park J, Jung ME et al. Conformational dynamics of androgen receptors bound to agonists and antagonists. Sci. Rep. 11(1), 15887 (2021).
   PubMed Web of Science ®Google Scholar
• Desai K, Mcmanus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr. Rev. 42(3), 354–373 (2021).
   PubMed Web of Science ®Google Scholar
• Clegg NJ, Wongvipat J, Joseph JD et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res. 72(6), 1494–1503 (2012).
   PubMed Web of Science ®Google Scholar
• Zhao J, Ning S, Lou W et al. Cross-resistance among next-generation antiandrogen drugs through the AKR1C3/AR-V7 axis in advanced prostate cancer. Mol. Cancer Ther. 19(8), 1708–1718 (2020).
   Web of Science ®Google Scholar
• Qin X, Ji D, Gu W et al. Activity and safety of SHR3680, a novel antiandrogen, in patients with metastatic castration-resistant prostate cancer: a phase I/II trial. BMC Med. 20(1), 84 (2022).
   Web of Science ®Google Scholar
• Auchus RJ, Yu MK, Nguyen S et al. Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer. Oncologist 19(12), 1231–1240 (2014).
   PubMed Web of Science ®Google Scholar
• Agarwal N, Tangen CM, Hussain MHA et al. Orteronel for metastatic hormone-sensitive prostate cancer: a multicenter, randomized, open-label phase III trial (SWOG-1216). J. Clin. Oncol. 40(28), 3301–3309 (2022).
   Web of Science ®Google Scholar
• Davis ID, Martin AJ, Stockler MR et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381(2), 121–131 (2019).
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Chen YH, Carducci M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373(8), 737–746 (2015).
   PubMed Web of Science ®Google Scholar
• Miura Y, Hatakeyama S, Narita S et al. Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration-sensitive prostate cancer: a multicenter retrospective study. Prostate 82(13), 1304–1312 (2022).
   Web of Science ®Google Scholar
• Narita S, Kimura T, Hatakeyama S et al. Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy. World J. Urol. 40(5), 1135–1141 (2022).
   Web of Science ®Google Scholar